LG Chem Signs Partnership with Chinese TransThera for Immunological Disease New Drug Development

Transfer of Clinical Development and Commercialization Rights in China
Expanding Partnership Following Introduction of NASH Treatment Candidate Substance

Researchers at LG Chem's Life Sciences Division are conducting new drug research. (Photo by LG Chem)

[Asia Economy Reporter Kim Ji-hee] LG Chem announced on the 28th that it has signed a partnership agreement with China's TransThera Biosciences for the autoimmune disease treatment candidate 'LC510255.' LC510255 is an oral new drug that promotes the expression of S1P1 (sphingosine-1-phosphate receptor-1), a hypersensitive immune function regulatory protein. Through preclinical and Phase 1 clinical trials, LG Chem confirmed its immune cell reduction effect and high selectivity for the S1P1 protein.

Under this agreement, TransThera will have exclusive development and commercialization rights for LC510255 in the Chinese market. LG Chem retains the global development and commercialization rights outside the Chinese market. Both companies plan to strengthen their strategic partnership based on their experience in the development rights regions to accelerate new drug development.

TransThera is a biotech company specializing in inflammatory diseases and anticancer drug development, founded in 2016 in Nanjing, China, by executives from multinational pharmaceutical companies. Last year, LG Chem confirmed the competitiveness of a non-alcoholic steatohepatitis (NASH) treatment candidate being developed by TransThera and signed a candidate substance introduction contract.

According to the market research firm GlobalData, the global market size for inflammatory bowel disease treatments such as ulcerative colitis and Crohn's disease exceeded 17 trillion KRW last year. It is expected to grow to 26 trillion KRW by 2027.

Son Ji-woong, head of the Life Sciences Business Division, said, "We will do our best to provide new treatment opportunities for autoimmune disease patients through successful new drug development," adding, "Based on an enhanced growth foundation including an expanded new drug pipeline and global partnerships, we will further accelerate our global market penetration."

This content was produced with the assistance of AI translation services.